RE:RE:RE:Licensing agreement?Gilles has stated before that if they receive positive bioavailabitly results, they will move ahead to out license the tech. It'll be up to companies to partner with CZO and conduct any efficacy studies they wish as each bioactive would require their own study.
In the SCD interview at the 1hr 14 min. mark, Gilles said he would present positive PGX alginate CoQ10 bioavailability data to the functional drink companies. They were interested before, but oat BG was too expensive to process to use as a carrier, this is why they tried alternate substrates.
Having a partner sign up for co-development of applications of PGX would definitely help accelerate the commercialization of PGX. Just as they can produce pharma grade AV pills for their phase 1 study, they'll still be able to provide new chemical complexes for clnical studies to partners as needed. One licensing model could be that Ceapro would receive milestone payments, then royalties if they allow the licencee to produce specific new chemical complexes. Would the licencee then be responsible to build their own mfg equipment at their own plant under Ceapro's technical guidance? This would definitely accelerate the timeline for a commercial product.
Keep in mind that Ceapro is likely keeping all options open.
Stinzo wrote: Must be something about company culture that I do not understand ...
you announce the licensing of some spaces for scale up but do not provide any idea of cost and timing? For a company that moves quiet slowly, you would expect them to have all this information on hand by now, they have been studying this scale up for 12-24 months?
The way I read the article, is that only once this new 5-10 x demo plant is built will they be able to test products for future possible partnerships ...
I guess the market is acting like I am, very confused ... just waiting for Q3 results really at this point.